Another drug in the pipeline for CLL that is p... - CLL Support
Another drug in the pipeline for CLL that is progressing to trials
You need to be a member of this community to see this post.
Read more about...
11 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD Provided by Clinical Care Options, LLC
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD
An installment...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
BTK Degrader Shows Potential for Treating Refractory CLL and SLL
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients...
Related Posts
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'- Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
- LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase. Phase 1 trial results.
- Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
